Al-Daccak R - Search Results

1

MHC class II signaling in antigen-presenting cells.

Al-Daccak R, Mooney N, Charron D. Al-Daccak R, et al. Curr Opin Immunol. 2004 Feb;16(1):108-13. doi: 10.1016/j.coi.2003.11.006. Curr Opin Immunol. 2004. PMID: 14734118 Review.

2

Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.

Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, Sylla K, Aoudjit F, Charron D, Al-Daccak R, Alcaide-Loridan C. Martins I, et al. Eur J Immunol. 2007 Mar;37(3):788-97. doi: 10.1002/eji.200636620. Eur J Immunol. 2007. PMID: 17304627 Free article.

3

The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes.

Doisne JM, Castaigne JG, Deruyffelaere C, Dieu-Nosjean MC, Chamot C, Alcaide-Loridan C, Charron D, Al-Daccak R. Doisne JM, et al. Mol Immunol. 2008 Feb;45(3):709-18. doi: 10.1016/j.molimm.2007.07.019. Epub 2007 Aug 24. Mol Immunol. 2008. PMID: 17719638

4

MHC class II isotype-specific signaling complex on human B cells.

Lévéille C, Castaigne JG, Charron D, Al-Daccak R. Lévéille C, et al. Eur J Immunol. 2002 Aug;32(8):2282-91. doi: 10.1002/1521-4141(200208)32:8<2282::AID-IMMU2282>3.0.CO;2-M. Eur J Immunol. 2002. PMID: 12209641 Free article.

5

Signaling through HLA-DR induces PKC beta-dependent B cell death outside rafts.

Guo W, Castaigne JG, Mooney N, Charron D, Al-Daccak R. Guo W, et al. Eur J Immunol. 2003 Apr;33(4):928-38. doi: 10.1002/eji.200323351. Eur J Immunol. 2003. PMID: 12672059 Free article.

6

Class II transactivator (CIITA) isoform expression and activity in melanoma.

Baton F, Deruyffelaere C, Chapin M, Prod'homme T, Charron D, Al-Daccak R, Alcaide-Loridan C. Baton F, et al. Melanoma Res. 2004 Dec;14(6):453-61. doi: 10.1097/00008390-200412000-00004. Melanoma Res. 2004. PMID: 15577315

7

Immunogenicity and allogenicity: a challenge of stem cell therapy.

Charron D, Suberbielle-Boissel C, Al-Daccak R. Charron D, et al. J Cardiovasc Transl Res. 2009 Mar;2(1):130-8. doi: 10.1007/s12265-008-9062-9. Epub 2008 Sep 26. J Cardiovasc Transl Res. 2009. PMID: 20559977 Review.

8

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R, Michel L. Hemon P, et al. J Immunol. 2011 May 1;186(9):5173-83. doi: 10.4049/jimmunol.1002050. Epub 2011 Mar 25. J Immunol. 2011. PMID: 21441454

9

Anti-HLA antibodies in regenerative medicine stem cell therapy.

Charron D, Suberbielle-Boissel C, Tamouza R, Al-Daccak R. Charron D, et al. Hum Immunol. 2012 Dec;73(12):1287-94. doi: 10.1016/j.humimm.2012.06.010. Epub 2012 Jul 10. Hum Immunol. 2012. PMID: 22789622 Review.

10

Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.

Boukouaci W, Al-Daccak R, Dulphy N, Lauden L, Amokrane K, Fortier C, Marzais F, Bennabi M, Peffault de Latour R, Socie G, Toubert A, Charron D, Krishnamoorthy R, Tamouza R. Boukouaci W, et al. Hum Immunol. 2013 Dec;74(12):1536-41. doi: 10.1016/j.humimm.2013.08.281. Epub 2013 Aug 29. Hum Immunol. 2013. PMID: 23994587

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page